ProCE Banner Activity

How I Use New Targeted Agents to Improve Outcomes for My Patients With AML

Clinical Thought
Here are my thoughts on how best to apply the recently approved targeted agents gemtuzumab ozogamicin, midostaurin, and enasidenib to improve outcomes for your patients with acute myeloid leukemia.

Released: October 12, 2017

Expiration: October 11, 2018

No longer available for credit.

Share

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by educational grants from

Astellas Text

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals Inc

Pfizer, Inc.